{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:06:46Z","timestamp":1789693606099,"version":"4.0.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007915","name":"Baylor College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008540","name":"Diana Helis Henry Medical Research Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtcvsonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtcvs.2026.02.030","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:52:36Z","timestamp":1772643156000},"page":"433-449.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tumor-infiltrating natural killer cell profiling for therapeutic stratification in patients with resectable non\u2013small cell lung cancer"],"prefix":"10.1016","volume":"172","author":[{"given":"Atsushi","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Wook","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Seon","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Ranchod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gena","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyeon","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayu H.","family":"Syarif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyoung","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younghun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Malo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Taylor","family":"Ripley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn S.","family":"Groth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrah","family":"Kheradmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan M.","family":"Burt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Polverino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher I.","family":"Amos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8259-046X","authenticated-orcid":false,"given":"Hyun-Sung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jtcvs.2026.02.030_bib1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"New Engl J Med"},{"issue":"17","key":"10.1016\/j.jtcvs.2026.02.030_bib2","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"New Engl J Med"},{"issue":"10027","key":"10.1016\/j.jtcvs.2026.02.030_bib3","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"10066","key":"10.1016\/j.jtcvs.2026.02.030_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jtcvs.2026.02.030_bib5","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"New Engl J Med"},{"issue":"35","key":"10.1016\/j.jtcvs.2026.02.030_bib6","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","article-title":"Nivolumab versus docetaxel in previously treated patients with advanced non\u2013small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)","volume":"35","author":"Horn","year":"2017","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.jtcvs.2026.02.030_bib7","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejca.2018.06.031","article-title":"Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study","volume":"101","author":"Horn","year":"2018","journal-title":"Eur J Cancer"},{"issue":"16","key":"10.1016\/j.jtcvs.2026.02.030_bib10","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1158\/1078-0432.CCR-17-0540","article-title":"U.S. food and drug administration approval summary: atezolizumab for metastatic non-small cell lung cancer","volume":"23","author":"Weinstock","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"10030","key":"10.1016\/j.jtcvs.2026.02.030_bib11","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jtcvs.2026.02.030_bib12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.jtcvs.2026.02.030_bib13","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1634\/theoncologist.2017-0078","article-title":"FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond","volume":"22","author":"Pai-Scherf","year":"2017","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.jtcvs.2026.02.030_bib14","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jtcvs.2026.02.030_bib15","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S1470-2045(19)30407-3","article-title":"Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis","volume":"20","author":"Antonia","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fmed.2020.00090","article-title":"Immunotherapy: from advanced NSCLC to early stages, an evolving concept","volume":"7","author":"Berghmans","year":"2020","journal-title":"Front Med"},{"issue":"12","key":"10.1016\/j.jtcvs.2026.02.030_bib17","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtcvs.2026.02.030_bib18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jtho.2020.09.022","article-title":"Atezolizumab versus docetaxel in pretreated patients with NSCLC: final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials","volume":"16","author":"Mazieres","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"21","key":"10.1016\/j.jtcvs.2026.02.030_bib19","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non\u2013small-cell lung cancer with PD-L1 tumor proportion score \u2265 50%","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jtcvs.2026.02.030_bib20","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non\u2013small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jtcvs.2026.02.030_bib21","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.22.01503","article-title":"Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non\u2013small-cell lung cancer in CheckMate 227","volume":"41","author":"Brahmer","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtcvs.2026.02.030_bib22","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial","volume":"28","author":"Gogishvili","year":"2022","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.jtcvs.2026.02.030_bib23","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/jamaoncol.2021.2209","article-title":"Nivolumab plus ipilimumab vs nivolumab for previously treated patients with stage IV squamous cell lung cancer: the lung-MAP S1400I phase 3 randomized clinical trial","volume":"7","author":"Gettinger","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.jtcvs.2026.02.030_bib24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jtho.2021.09.010","article-title":"First-Line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial","volume":"17","author":"Paz-Ares","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"21","key":"10.1016\/j.jtcvs.2026.02.030_bib25","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jtcvs.2026.02.030_bib26","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jtcvs.2026.02.030_bib27","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO-24-02239","article-title":"Neoadjuvant nivolumab plus ipilimumab versus chemotherapy in resectable lung cancer","volume":"43","author":"Awad","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jtcvs.2026.02.030_bib28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non\u2013small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jtcvs.2026.02.030_bib29","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jtcvs.2026.02.030_bib30","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1158\/0008-5472.CAN-21-3506","article-title":"Therapeutic targeting of macrophage plasticity remodels the tumor-immune microenvironment","volume":"82","author":"Jang","year":"2022","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.jtcvs.2026.02.030_bib31","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jtcvs.2019.10.123","article-title":"Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors","volume":"159","author":"Jang","year":"2020","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"6","key":"10.1016\/j.jtcvs.2026.02.030_bib32","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jtho.2024.02.009","article-title":"Neoadjuvant chemoimmunotherapy complicates subsequent surgical resection and adjuvant immunotherapy is preferable from the surgical standpoint","volume":"19","author":"Ugalde Figueroa","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.jtcvs.2026.02.030_bib33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jtcvs.2026.02.030_bib34","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/SLA.0b013e31822d7f81","article-title":"The attributable risk of smoking on surgical complications","volume":"254","author":"Hawn","year":"2011","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.jtcvs.2026.02.030_bib35","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1378\/chest.113.4.883","article-title":"Preoperative smoking habits and postoperative pulmonary complications","volume":"113","author":"Bluman","year":"1998","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.jtcvs.2026.02.030_bib36","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.athoracsur.2009.04.035","article-title":"Impact of smoking cessation before resection of lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database study","volume":"88","author":"Mason","year":"2009","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1016\/j.jtcvs.2026.02.030_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266052","article-title":"Impact of smoking status and chronic obstructive pulmonary disease on pulmonary complications post lung cancer surgery","volume":"17","author":"Jeganathan","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jtcvs.2026.02.030_bib38","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jtcvs.2017.08.138","article-title":"The eighth edition TNM stage classification for lung cancer: what does it mean on main street?","volume":"155","author":"Detterbeck","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"13","key":"10.1016\/j.jtcvs.2026.02.030_bib39","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1158\/1078-0432.CCR-24-4024","article-title":"Ad-SGE-DKK3 gene therapy overcomes resistance to immune checkpoint blockade in Pleural Mesothelioma","volume":"31","author":"Jang","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14049","article-title":"Massively parallel digital transcriptional profiling of single cells","volume":"8","author":"Zheng","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","article-title":"Dictionary learning for integrative, multimodal and scalable single-cell analysis","volume":"42","author":"Hao","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nbt.4314","article-title":"Dimensionality reduction for visualizing single-cell data using UMAP","volume":"37","author":"Becht","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib43","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41467-020-15351-4","article-title":"Dimensionality reduction by UMAP to visualize physical and genetic interactions","volume":"11","author":"Dorrity","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib44","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cell.2015.05.047","article-title":"Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis","volume":"162","author":"Levine Jacob","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib45","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib46","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib47","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051862","article-title":"Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization","volume":"7","author":"Budczies","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib49","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41467-020-16164-1","article-title":"Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4049\/jimmunol.179.1.89","article-title":"CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts","volume":"179","author":"Chan","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12171","article-title":"Human NK cell development requires CD56-mediated motility and formation of the developmental synapse","volume":"7","author":"Mace","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib52","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1073\/pnas.1323845111","article-title":"Polyclonal type II natural killer T cells require PLZF and SAP for their development and contribute to CpG-mediated antitumor response","volume":"111","author":"Zhao","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib53","doi-asserted-by":"crossref","first-page":"7602","DOI":"10.1073\/pnas.1601504113","article-title":"Multiple layers of transcriptional regulation by PLZF in NKT-cell development","volume":"113","author":"Mao","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13116","article-title":"Distinct gene expression patterns correlate with developmental and functional traits of iNKT subsets","volume":"7","author":"Georgiev","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101709","article-title":"FcR\u03b3 gene editing reprograms conventional NK cells to display key features of adaptive human NK cells","volume":"23","author":"Liu","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib56","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib57","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1126\/science.aad2035","article-title":"Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes","volume":"352","author":"Mackay","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib58","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.immuni.2023.01.016","article-title":"Infection induces tissue-resident memory NK cells that safeguard tissue health","volume":"56","author":"Schuster","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib59","first-page":"233","article-title":"Role of the CX3CL1-CX3CR1 axis in chronic inflammatory lung diseases","volume":"3","author":"Zhang","year":"2010","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib60","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.4049\/jimmunol.176.3.1517","article-title":"CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity","volume":"176","author":"Hayakawa","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib61","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.4049\/jimmunol.1600590","article-title":"Killer cell lectin-like receptor G1 inhibits NK cell function through activation of adenosine 5'-monophosphate-activated protein kinase","volume":"197","author":"M\u00fcller-Durovic","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1044398","article-title":"Single-cell transcriptomics in bone marrow delineates CD56dimGranzymeK+ subset as intermediate stage in NK cell differentiation","volume":"13","author":"Melsen","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib63","doi-asserted-by":"crossref","first-page":"18360","DOI":"10.1073\/pnas.1110584108","article-title":"Natural killer (NK)-dendritic cell interactions generate MHC class II-dressed NK cells that regulate CD4+ T cells","volume":"108","author":"Nakayama","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib64","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/JLB.3RU0420-668RR","article-title":"HLA-DR-expressing NK cells: effective killers suspected for antigen presentation","volume":"109","author":"Erokhina","year":"2021","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib65","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.4049\/jimmunol.162.5.2453","article-title":"Cutting edge: a role for the adaptor protein LAT in human NK cell-mediated Cytotoxicity1","volume":"162","author":"Jevremovic","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib66","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fimmu.2016.00176","article-title":"Signaling in effector lymphocytes: insights toward safer immunotherapy","volume":"7","author":"Rajasekaran","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib67","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1038\/s41467-019-11947-7","article-title":"Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome","volume":"10","author":"Yang","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib68","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13073-023-01164-9","article-title":"Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing","volume":"15","author":"Hu","year":"2023","journal-title":"Genome Med"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib69","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jtcvs.2022.12.006","article-title":"Safety and feasibility of minimally invasive lobectomy after neoadjuvant immunotherapy for non-small cell lung cancer","volume":"166","author":"Mathey-Andrews","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib70","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamaoncol.2024.0057","article-title":"Neoadjuvant chemoimmunotherapy for NSCLC: a systematic review and meta-analysis","volume":"10","author":"Sorin","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib71","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241312501","article-title":"Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies","volume":"17","author":"Chen","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib72","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib73","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib74","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jtho.2022.09.109","article-title":"Predictive biomarkers for immunotherapy in lung cancer: perspective from the international association for the study of lung cancer pathology committee","volume":"17","author":"Mino-Kenudson","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib75","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/jamaoncol.2022.1981","article-title":"Association of high tumor mutation burden in non\u2013small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels","volume":"8","author":"Ricciuti","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib76","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib77","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jamaoncol.2018.7098","article-title":"Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non\u2013small cell lung cancer with use of a next-generation sequencing cancer gene panel","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib78","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41591-022-01754-x","article-title":"Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial","volume":"28","author":"Kim","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib79","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib80","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omto.2021.11.016","article-title":"Natural killer cells and immune-checkpoint inhibitor therapy: current knowledge and new challenges","volume":"24","author":"Poggi","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib81","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib82","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41419-022-05057-4","article-title":"Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC)","volume":"13","author":"Hui","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib83","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-Unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib84","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1158\/2159-8290.CD-23-0519","article-title":"NKG2A is a therapeutic vulnerability in immunotherapy resistant MHC-I heterogeneous triple-negative breast cancer","volume":"14","author":"Taylor","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib85","article-title":"Advances in CAR-NK cell therapy for lung cancer: is it a better choice in the future?","volume":"14","author":"Liu","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtcvs.2026.02.030_bib86","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat Rev Cancer"}],"container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002252232600187X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002252232600187X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:43:05Z","timestamp":1789692185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002252232600187X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S002252232600187X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtcvs.2026.02.030","relation":{"has-preprint":[{"id-type":"doi","id":"10.64898\/2026.01.01.696292","asserted-by":"object"}]},"ISSN":["0022-5223"],"issn-type":[{"value":"0022-5223","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor-infiltrating natural killer cell profiling for therapeutic stratification in patients with resectable non\u2013small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"The Journal of Thoracic and Cardiovascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtcvs.2026.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery.","name":"copyright","label":"Copyright"}]}}